<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Vascular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> protein-1 (VAP-1) participates in <z:mp ids='MP_0001845'>inflammation</z:mp> and catalyzes the breakdown of <z:chebi fb="39" ids="32952">amines</z:chebi> to produce <z:chebi fb="1" ids="17478">aldehyde</z:chebi>, <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi>, and ammonia </plain></SENT>
<SENT sid="1" pm="."><plain>Serum VAP-1 correlates positively with both <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital </plain></SENT>
<SENT sid="4" pm="."><plain>Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay </plain></SENT>
<SENT sid="5" pm="."><plain>The vital status of <z:hpo ids='HP_0000001'>all</z:hpo> subjects was ascertained by linking their data with computerized <z:hpo ids='HP_0011420'>death</z:hpo> certificates in Taiwan </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The medium follow-up period was 10.4 years </plain></SENT>
<SENT sid="7" pm="."><plain>Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17-4.11) for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality adjusted for age, sex, smoking, history of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A(1c), <z:mp ids='MP_0002055'>diabetes</z:mp> duration, total cholesterol, use of <z:chebi fb="0" ids="35664">statins</z:chebi>, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17-28.97) for cardiovascular mortality, 6.32 (95% CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57-65.07) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="9" pm="."><plain>There were four variables, including age, serum VAP-1, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, and eGFR, which could enhance mortality prediction significantly </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Serum VAP-1 can predict 10-year <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, cardiovascular mortality, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality independently in type 2 diabetic subjects </plain></SENT>
<SENT sid="11" pm="."><plain>Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors </plain></SENT>
</text></document>